SynthesisWorld journal of gastroenterology2013
FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis.
Synthesis in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 3 syntheses or guidelines pooled it, 146 citations in OpenAlex.
- Diagnostic performance of F-18 FDG PET/CT in differentiating autoimmune pancreatitis from pancreatic cancer: a systemic review and meta-analysis.Annals of nuclear medicine · 2024Pooled it
- Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis.Medicine · 2017Pooled it
- Pooled it
- Intraoperative Molecular Imaging Combined With Positron Emission Tomography Improves Surgical Management of Peripheral Malignant Pulmonary Nodules.Annals of surgery · 2017Trial
- Diagnostic performance of ¹⁸F-FDG PET/CT radiomics-based machine learning models for pancreatic lesion characterisation: Comparison with visual assessment and evaluation of human-radiomics synergy.European journal of nuclear medicine and molecular imaging · 2026Article
- A pilot study of nectin-4-targeted radioligand [European journal of nuclear medicine and molecular imaging · 2026Article
- The Role of Molecular Imaging in Ion Beam Therapy.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Advances in nanomaterial-enhanced immunosensors for ultra-sensitive tumor marker detection: Enabling early cancer diagnostics.Frontiers in chemistry · 2026Review
- Unlocking drug development: the distinctive roles of PET and SPECT imaging from molecular kinetics to therapeutic response.Archives of pharmacal research · 2026Review
- Recent Advances in Nanotechnology-Based Approaches for Ferroptosis Therapy and Imaging Diagnosis in Pancreatic Cancer.Pharmaceutics · 2025Review
- Diagnostic accuracy of dual-phaseScientific reports · 2025Article
- Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication.European journal of nuclear medicine and molecular imaging · 2024Review
- Prospective Comparison of [Molecular imaging and biology · 2024Article
- Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi-omics analysis.Cancer science · 2024Article
- Differentially expressed genes associated with high metabolic tumor volume served as diagnostic markers and potential therapeutic targets for pancreatic cancer.Journal of translational medicine · 2024Article
- αvβ6-integrin targeted PET/CT imaging in pancreatic cancer patients usingFrontiers in nuclear medicine · 2024Article
- Review
- Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Upfront Surgery.Annals of surgical oncology · 2023Article
- Article
- Contrast-Enhanced Harmonic Endoscopic Ultrasound-Guided Puncture for the Patients with Pancreatic Masses.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the potential role of positron emission tomography (PET) in the diagnosis, staging and prognosis predicting of pancreatic carcinoma (PC).
methodsA systematic review of relevant literatures in PubMed, Embase and Cochrane Library was performed. The sensitivity and specificity of diagnostic and staging studies, and HRs for prognosis predicting studies were pooled. The bivariate model was used for diagnostic studies and the random-effect model for prognostic studies. Heterogeneity between included studies was tested using χ(2) test, and subgroup analysis was performed to explain the heterogeneities. All of the calculations were performed using Stata version 11.0.
resultsA total of 39 studies were included. The pooled sensitivity of PET in diagnosing PC (30 studies, 1582 patients), evaluating N stating (4 studies, 101 patients) and liver metastasis (7 studies, 316 patients) were 0.91 (95%CI: 0.88-0.93), 0.64 (95%CI: 0.50-0.76), and 0.67 (95%CI: 0.52-0.79), respectively; and the corresponding specificity was 0.81 (95%CI: 0.75-0.85), 0.81 (95%CI: 0.25-0.85), and 0.96 (95%CI: 0.89-0.98), respectively. In prognosis analysis (6 studies, 198 patients), significant difference of overall survival was observed between high and low standardized uptake value groups (HR = 2.39, 95%CI: 1.57-3.63). Subgroup analysis showed that PET/CT was more sensitive than PET alone in evaluating liver metastasis of PC, 0.82 (95%CI: 0.48-0.98) and 0.67 (95%CI: 0.52-0.79), respectively.
conclusionPET can be used as a valuable diagnostic and predictive tool for PC, but its effect in the staging of PC remains indeterminate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.